Technology ID
TAB-4870
Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants
E-Numbers
E-048-2020-0
Lead Inventor
Dekosky, Brandon
Lead IC
NIAID
Co-Inventors
Jin, Wei
Kwong, Peter
Kwon, Young Do
Zhang, Baoshan
ICs
NIAID
Applications
Therapeutics
Development Stages
Discovery
Research Products
Research Equipment
Plasmids/Vectors
Computational models/software
Antibodies
This technology involves the development of lgG1 Fe variants designed to interact more effectively with the neonatal Fc receptor (FcRn) in a pH-dependent manner. By enhancing this interaction, these variants extend the serum half-life of therapeutic antibodies, reducing the need for frequent administration. This breakthrough holds the potential to make therapeutic antibody treatments more convenient, cost-effective, and accessible for a wide range of diseases.
Commercial Applications
The extended serum half-life of these lgG1 Fe variants holds promise across a wide range of therapeutic antibody treatments, including oncology, autoimmune disorders, and infectious diseases. This innovation may enhance treatment effectiveness and convenience in various medical fields.
Competitive Advantages
These lgG1 Fe variants possess a unique competitive edge in the therapeutic antibody arena. Their pH-dependent interaction with FcRn extends serum half-life, reducing the need for frequent dosing. This enhanced convenience not only benefits patients but also lowers treatment costs, making these variants an attractive choice for healthcare providers. By addressing the challenges of short serum half-life and high production costs, this technology offers a compelling solution, enhancing the feasibility and affordability of antibody-based therapies for various diseases.
Licensing Contact: